|
Consensus recommendations |
Grade |
|
All individuals with cirrhosis should be enrolled in HCC screening programs. |
A1 |
|
All individuals with cirrhosis should be offered DAA treatment for HCV infection. |
A1 |
|
People with cirrhosis and prior HCC should be closely monitored for HCC recurrence during and after DAA therapy for HCV infection. |
B2 |
|
HCC screening for all individuals with no cirrhosis is not cost-effective. |
A1 |